Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease

NCT01949532 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01949532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
January 31, 2017
Enrollment
26 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease, relapsed multiple myeloma